Thu, 10 December 2015
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Direct download: GRACEcast-413_WCLC_2015_Clinically_Significant_Differences_Second_Generation_ALK_Inhibitors.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST